AORT earnings analysis
What we found in AORT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Artivion delivered a strong Q2 2026, with revenue of $125.757 million, up 8.4% sequentially and 11.3% year over year, while diluted EPS increased to $0.13 from $0.03 in both comparison periods. Results exceeded consensus for both revenue and EPS, and the Endospan acquisition expanded the company’s aortic portfolio through the NEXUS products. The principal risks are geopolitical and supply-chain exposure at the Israel-based NEXUS facility, a potential Italian government repayment of approximately $2.3 million, and uncertainty surrounding recent U.S. tax and healthcare legislation.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Accelerated
- Q2 revenue was $125.757 million, up from $116 million in Q1 2026 and $113 million in Q2 2025, representing approximately 8.4% sequential growth and 11.3% year-over-year growth.
- EPS Improved and Beat Estimates
- Diluted EPS was $0.13 versus $0.03 in both Q1 2026 and Q2 2025. EPS also exceeded the $0.10 consensus estimate by $0.03.
- Revenue Beat Estimates
- Revenue exceeded the $120.19 million consensus estimate by $5.567 million, or approximately 4.6%.
- Endospan Adds Aortic Portfolio
- The Endospan acquisition closed on May 18, 2026, adding the NEXUS product family and a manufacturing facility in Herzliya, Israel.
- Controls Remain Effective
- Management reported no material change in market-risk disclosures as of June 30, 2026, and concluded that disclosure controls were effective at a reasonable assurance level.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- NEXUS Israel Supply Exposure
- The acquired NEXUS family of products is solely manufactured in Herzliya, Israel. The filing states that no material NEXUS supply disruption has occurred from the war in Iran, but escalation could cause shortages, freight delays, higher costs, or other supply-chain disruptions.
- Italian Payback Liability
- The Italian government is assessing medical-device spending amounts for 2019-2024, and Artivion estimates potential repayment exposure for the entire 2019-2025 period at approximately $2.3 million.
- U.S. Tax and Healthcare Changes
- The filing highlights that the July 4, 2025 One Big Beautiful Bill Act changes U.S. tax and healthcare laws, including corporate tax and business-deduction provisions; interpretive guidance could adversely affect results, although the company has not yet quantified the impact.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.13
What they said about what is next.
The provided 10-Q extract does not include a quantitative outlook or explicit guidance update. The prior Q1 2026 outlook was revenue of $480 million-$496 million, but the current filing text does not state whether that outlook was maintained, raised, or lowered.
The filing reads better than the one before it.
What came before.
- 10-Q · May 8, 2026
- Artivion reported Q1 2026 results with revenues of $116.3 million, reflecting an 18% year-over-year growth, but EPS came in lower at $0.08 against the estimate of $0.11. The company revised its full-year revenue…
- 10-K · February 18, 2026
- Artivion’s 2025 results show top-line recovery and margin stability: quarterly revenue climbed to $116M in 2025Q4 and full-year revenue totaled roughly $441M (sum of 2025 quarters). Gross margins remained around the…
- 10-Q · November 7, 2025
- Artivion reported Q3 2025 revenue of $113,388,000 and gross margin of $74,395,000 (≈65.6%), driving operating income of $12,536,000 and GAAP net income of $6,502,000 (diluted EPS $0.13). The quarter shows meaningful…
- 10-Q · August 8, 2025
- Artivion reported Q2 revenue of $112,972,000, up $14,953,000 versus Q2 2024 ($98,019,000), with gross margin of 64.7% and operating income of $8,384,000 (7.4% operating margin). GAAP diluted EPS was $0.03 and net income…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing AORT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever